The global Graft Versus Host Disease Market was valued at $2,968.6 million in 2021, and is projected to reach $10,375.3 million by 2031, registering a CAGR of 13.5% from 2022 to 2031.
Graft versus host disease (GVHD) is a condition that might occur after an allogeneic transplant (bone marrow transplant). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign, and the donated cells/bone marrow attack the body. There are two forms of GVHD: acute graft versus host disease (aGVHD) and chronic graft versus host disease (cGVHD).
The pathophysiology of aGVHD and cGVHD remains incompletely understood. One commonly quoted model suggests three distinct stages in the development of aGVHD: a conditioning regimen, which damages host tissues, including intestinal mucosa and liver; activation of donor T cells against host antigens & subsequent clonal T-cell expansion; and release of inflammatory cytokines such as interleukin 1 (IL-1) & tumor necrosis factor (TNFα), leading to further host tissue damage. Several mechanisms have been implicated in cGVHD pathogenesis, including persistence of donor-derived alloreactive T cells, autoreactive T cells, B cells producing antibodies against the host, and mechanisms of chronic inflammation leading to end organ fibrosis.
Despite decades of research and improvements in post-transplant immunosuppressive therapies, graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality in allogenic hematopoietic stem-cell transplant (HSCT) recipients.
The COVID-19 pandemic has had an impact on a variety of businesses around the world. The Graft Versus Host Disease Market had a significant impact as well. To halt the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe work to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.
As kidney transplantation rates declined, so did organ procurement rates. The UK reported a 39% decrease in referrals of organs to OPOs. France reported a 16% decrease in all deceased organ procurement rates as compared to previous years. Part of these declines were due to procurement challenges faced by transplant programs and organizations, such as insufficient testing capabilities and delayed COVID-19 test results, limited operating room availabilities, and mandates for the avoidance of nonessential clinical activities to preserve personnel and protective equipment.
Therefore, the overall impact of COVID-19 remains negative on graft versus host disease market due to decline in number of transplantation procedure. The transplant procedure requires the routine use of reusable equipment with close contact with patients. This increases the risk of disease transmission.
Increase in number of grafts versus host disease, which arises predominantly due to rise in number of allogenic transplantations. Also, increase in disease diagnosis rate and increase in number of products available for the treatment of graft versus host disease are the factors fueling the growth of the market.
According to preliminary data from the Organ Procurement and Transplantation Network, in 2020 organ donation from deceased donors in the U.S. set an all-time record. A total of 12,587 people provided one or more organs to save and enhance the lives of others, representing an increase of six percent over 2019.
Moreover, much of the increase in deceased donation was made possible by donors representing less traditional medical criteria. The most common age range of deceased donors was 50 to 64. The 3,726 donors in this category increased by 7.9 percent over 2019. Donation increased significantly among individuals who died of cardiorespiratory failure as opposed to brain death; the 3,223 donors after cardiorespiratory death (DCD donors) increased by 18.6 percent over the total in 2019.
According to Organ Donation Statistics, 105,988 number of men, women, and children are on the national transplant waiting list, whereas 17 people die each day waiting for the organ transplant and an estimated 40,000 transplants were performed in 2021.
Complications such as allergic reactions, which cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, the high initial cost and maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce are expected to be the significant restraints to market growth during the forecast period.
The graft versus host disease market is segmented on the basis of product, diagnosis, types, end use, and region. By product the market is segmented into corticosteroids, monoclonal antibodies, immunosuppressants and others. On the basis of type the segment is divided into acute and chronic. On the basis of end use the segment is divided into hospital pharmacies, retail pharmacies and online pharmacies.
Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the graft versus host disease market are AbbVie, Asahi Kasei, Bristol Myer Squibb, GlaxoSmithKline, Incyte Corporation, Medac GmbH, Merck & co., Novartis, Pfizer and Sanofi.
It presents a quantitative analysis of the market from 2022 to 2031 to enable stakeholders to capitalize on the prevailing market graft versus host disease market opportunity.
Extensive analysis of the market based on procedures and services assists to understand the trends in the graft versus host disease industry.
Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Graft versus host disease (GVHD) is a condition that might occur after an allogeneic transplant (bone marrow transplant). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign, and the donated cells/bone marrow attack the body. There are two forms of GVHD: acute graft versus host disease (aGVHD) and chronic graft versus host disease (cGVHD).
The pathophysiology of aGVHD and cGVHD remains incompletely understood. One commonly quoted model suggests three distinct stages in the development of aGVHD: a conditioning regimen, which damages host tissues, including intestinal mucosa and liver; activation of donor T cells against host antigens & subsequent clonal T-cell expansion; and release of inflammatory cytokines such as interleukin 1 (IL-1) & tumor necrosis factor (TNFα), leading to further host tissue damage. Several mechanisms have been implicated in cGVHD pathogenesis, including persistence of donor-derived alloreactive T cells, autoreactive T cells, B cells producing antibodies against the host, and mechanisms of chronic inflammation leading to end organ fibrosis.
Despite decades of research and improvements in post-transplant immunosuppressive therapies, graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality in allogenic hematopoietic stem-cell transplant (HSCT) recipients.
The COVID-19 pandemic has had an impact on a variety of businesses around the world. The Graft Versus Host Disease Market had a significant impact as well. To halt the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe work to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.
Impact of COVID-19: The COVID-19 pandemic has significantly changed the landscape of kidney transplantation in the U.S. and worldwide. In addition to adversely impacting allograft and patient survival in post kidney transplant recipients, the current pandemic has affected all aspects of transplant care, including transplant referrals and listing, organ donation rates, organ procurement and shipping, and waitlist mortality.
As kidney transplantation rates declined, so did organ procurement rates. The UK reported a 39% decrease in referrals of organs to OPOs. France reported a 16% decrease in all deceased organ procurement rates as compared to previous years. Part of these declines were due to procurement challenges faced by transplant programs and organizations, such as insufficient testing capabilities and delayed COVID-19 test results, limited operating room availabilities, and mandates for the avoidance of nonessential clinical activities to preserve personnel and protective equipment.
Therefore, the overall impact of COVID-19 remains negative on graft versus host disease market due to decline in number of transplantation procedure. The transplant procedure requires the routine use of reusable equipment with close contact with patients. This increases the risk of disease transmission.
Increase in number of grafts versus host disease, which arises predominantly due to rise in number of allogenic transplantations. Also, increase in disease diagnosis rate and increase in number of products available for the treatment of graft versus host disease are the factors fueling the growth of the market.
According to preliminary data from the Organ Procurement and Transplantation Network, in 2020 organ donation from deceased donors in the U.S. set an all-time record. A total of 12,587 people provided one or more organs to save and enhance the lives of others, representing an increase of six percent over 2019.
Moreover, much of the increase in deceased donation was made possible by donors representing less traditional medical criteria. The most common age range of deceased donors was 50 to 64. The 3,726 donors in this category increased by 7.9 percent over 2019. Donation increased significantly among individuals who died of cardiorespiratory failure as opposed to brain death; the 3,223 donors after cardiorespiratory death (DCD donors) increased by 18.6 percent over the total in 2019.
According to Organ Donation Statistics, 105,988 number of men, women, and children are on the national transplant waiting list, whereas 17 people die each day waiting for the organ transplant and an estimated 40,000 transplants were performed in 2021.
Complications such as allergic reactions, which cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, the high initial cost and maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce are expected to be the significant restraints to market growth during the forecast period.
The graft versus host disease market is segmented on the basis of product, diagnosis, types, end use, and region. By product the market is segmented into corticosteroids, monoclonal antibodies, immunosuppressants and others. On the basis of type the segment is divided into acute and chronic. On the basis of end use the segment is divided into hospital pharmacies, retail pharmacies and online pharmacies.
Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the graft versus host disease market are AbbVie, Asahi Kasei, Bristol Myer Squibb, GlaxoSmithKline, Incyte Corporation, Medac GmbH, Merck & co., Novartis, Pfizer and Sanofi.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the graft versus host disease market, and the current graft versus host disease market trends and future estimations to elucidate imminent investment pockets.It presents a quantitative analysis of the market from 2022 to 2031 to enable stakeholders to capitalize on the prevailing market graft versus host disease market opportunity.
Extensive analysis of the market based on procedures and services assists to understand the trends in the graft versus host disease industry.
Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
Key Market Segments
By Product Type
- Corticosteroids
- Monoclonal antibodies
- Immunosuppressants
- Others
By Treatment Type
- Acute GVHD
- Chronic GVHD
By End Use
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Turkey
- South Africa
- Rest of LAMEA
Key Market Players
- Sanofi
- Novartis AG
- Merck & Co.
- Abbvie Inc
- Pfizer Inc.
- Accord Healthcare Limited
- Bristol Myer Squibb
- Asahi Kasei Corporation
- Glaxosmithkline plc
- Incyte Corporation
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE
CHAPTER 5: GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE
CHAPTER 6: GRAFT VERSUS HOST DISEASE MARKET, BY END USE
CHAPTER 7: GRAFT VERSUS HOST DISEASE MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Graft Versus Host Disease Market," the graft versus host disease market size was valued at $3.0 billion in 2021, and is estimated to reach $10.4 billion by 2031, growing at a CAGR of 13.5% from 2022 to 2031.Graft versus host disease is a condition that occurs when donated stem cells or bone marrow (the graft) see the healthy tissues in the patient’s body (the host) as foreign and attack them. It can also occur after an organ transplant. It can cause damage to the host’s tissues and organs, especially the skin, liver, intestines, eyes, mouth, hair, nails, joints, muscles, lungs, kidneys, and genitals. The signs and symptoms may be severe and life threatening. It can occur within the first few months after transplant (acute) or much later (chronic).
Based on when symptoms show up, there are two main types of GVHD. Acute GVHD usually happens within 100 days of the transplant. Chronic GVHD usually appears later, some of the symptoms of acute GVHD are rashes on palms & soles, ears, face, or shoulders, watery diarrhea, abdominal cramps, nausea, vomiting, or lack of appetite, low levels of red blood cells or platelets and fever. Whereas the symptoms of chronic GVHD are dry, irritated eyes & sensitivity to light, joint pain, dryness in mouth, brittle nails, hair loss, and wheezing or persistent cough.
Despite considerable advances in our understanding of the pathophysiology, diagnosis, and predisposing factors for both acute and chronic forms of the disease, a standardized therapeutic strategy still lacks. There is good evidence for initial treatment of both acute and chronic forms of the disease with corticosteroid therapy. Timely diagnosis, multidisciplinary working and good supportive care, including infection prophylaxis, are clearly important in optimizing response and survival in such patients.
Various drugs have been used for the treatment of GVHD, most of these drugs work by damping down (suppressing) the immune system. This stops the donated cells (graft) from attacking your body (host). The patients are at a greater risk of getting an infection if he/she have GVHD, as it weakens the immune system. Treatments for GVHD further increase this risk. Some of the categories of treatment available of GVHD are as follows- steroids, ciclosporin, tacrolimus, light treatment (ECP), monoclonal antibodies, mTOR inhibitor, tyrosine kinase inhibitor, etanercept, thalidomide, pentostatin, methotrexate etc.
The risk of developing GVHD can be lowered by giving the preventive (prophylactic) medicines to suppress the immune system after the transplant. These medicines are anticipated to decrease the ability of the donor's cells to start an immune response against the own tissues. Fungal, bacterial, and viral infections are major risks with this prophylactic medicine regimen, since the immune system is anticipated to be suppressed and have a decreased ability to fight infection. So, the patient is anticipated to be on prophylactic antibiotics, antifungals, and antiviral medicines to decrease infection risks.
Factors that drive growth of the graft versus host disease market size include increase in number of patients with GVHD complication. Many patients return home from transplant centers after haemopoietic cell transplantation (HCT) requiring continued treatment with immunosuppressive drugs. This leads to the increasing demand of immunosuppressive drugs which propels the growth of the graft versus host disease market trends.
For instance, in 2021, VCU Health Hume-Lee Transplant Center performed an astounding 494 transplants. The year before, it was 459. And before that, 434. With a national wait list of 97,392 registrations for kidneys and 11,494 for livers, some people won’t make it long enough to wait for the transplant and needs urgent transplantation requirement.
Surge in development of tissue typing labs and using more precise DNA level tests to select the best HLA matched donor for the patient and increased in R&D process new, and better, methods have been developed to prevent GVHD which are being studied in clinical trials. The use of photopheresis, different immunosuppressive drugs, and new prophylaxis medications given to recipients after transplant are examples of some of that research. Moreover, in May 2019, Incyte Corporation received FDA approval for ruxolitinib (Jakafi) for the treatment of steroid refractory acute graft versus host disease in adult and pediatric patients.
The graft versus host disease market share is segmented on the basis of product, type, end use, and region. On the basis of product, the market is segmented into corticosteroids, monoclonal antibodies, immunosuppressants, and others. On the basis of type, it is segmented into acute and chronic and on the basis of end use the segment is divided into hospital pharmacies, retail pharmacies and online pharmacies.
North America graft versus host disease industry accounted for a majority of the graft versus host disease market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed due to rise in number of transplantations, increase in number of geriatric populations suffering from liver & kidney disease, presence of key players and advancement in healthcare in the region. Asia-Pacific is anticipated to witness lucrative growth, owing to increase in the GVHD-prevalent population, advancements in the diagnostic measures of the disease, approval of novel treatments, and a greater range of prophylaxis options that are anticipated to lead to significant growth of the market in the near future.
According to Onkar Sumant, Manager, Healthcare, “The increase in the prevalence of cancer patients and surge in demand of hematopoietic transplantation procedures fuels the growth of graft versus host disease market analysis.”
Key players operating in the global graft versus host disease market forecast include AbbVie, Accord Healthcare Limited, Asahi Kasei, Bristol Myer Squibb, GlaxoSmithKline PLC, Incyte Corporation, Merck & Co, Novartis, Pfizer and Sanofi.
Key Findings of the Study
- By product, the immunosuppressants segment was the highest contributor to the graft versus host disease market trend in 2021.
- By type, the acute GVHD was the highest contributor to the graft versus host disease industry in 2021.
- By end use, the online pharmacies segment is projected to grow at a significant CAGR of 14.0% from 2022 to 2031.
- By region, North America garnered largest revenue share in 2021, whereas LAMEA is anticipated to grow at the highest CAGR of 15.9% during the review period.
Companies Mentioned
- Sanofi
- Novartis AG
- Merck & Co.
- Abbvie Inc
- Pfizer Inc.
- Accord Healthcare Limited
- Bristol Myer Squibb
- Asahi Kasei Corporation
- GlaxoSmithKline plc
- Incyte Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 230 |
| Published | June 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 2968.6 million |
| Forecasted Market Value ( USD | $ 10375.3 million |
| Compound Annual Growth Rate | 13.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
